| Popis: |
Objective: To compare the efcacy and safety between laser therapy and anti-vascular endothelial growth factor (VEGF) agents for aggressive retinopathy of prematurity (A-ROP). Acomparative study for laser, anti VEGF with laser and anti-VEGF mono therapy forPatients and methods: A-ROP treatment. Study period was 2016 to 2020 at BIRDEM General Hospital. We included fteen A-ROP babies with thirty eyes. Ten eyes treated with laser, ten eyes treated with anti-VEGF with laser and ten eyes treated with anti-VEGF. We used Bevacizumab as anti-VEGF. We compared efcacy, safety, complication, retreatment between these three groups. Complication incidences were signicantly higher inResult: laser therapy group. 20% of infants' needs retreatments with laser therapy more than two sessions. In anti-VEGF and laser therapy group, 6.7% of infants need retreatment and in anti-VEGF group-1 3.3% infants need retreatment. P-value was 0.005 which is signicant. Development of myopia is signicantly higher in laser therapy group (Group-3). About 100% infants' developed myopia. In Group-2 30% infants' developed myopia. In Group-1 no infants developed myopia. P-value was highly signicant 0.01. This analysis outcome indicates anti-VEGF agents are asConclusion: effective as laser treatment and safer than laser. The degree of myopia in A-ROP in laser group is higher than anti-VEGF mono therapy group. The decreased incidence of early unfavorable refractive and functional outcomes in the IVB group compared with the laser group showed a potential benet for patients treated with Intravitreal Bevacizumab (IVB). |
